Hepatokine-based identification of fibrotic NASH and improved risk stratification in a multicentre cohort of NAFLD patients.
Martin FranckKatharina JohnSherin Al AouaMonika RauAndreas GeierJörn Markus SchattenbergHeiner WedemeyerKlaus Schulze-OsthoffHeike BantelPublished in: Liver international : official journal of the International Association for the Study of the Liver (2023)
Serological FGF21 detection might allow the identification of NAFLD patients at risk and improves patient stratification in combination with FIB-4.